Alzamend Neuro公司宣布，其针对AL001（即“锂入脑”研究）的II期临床试验获得了积极的顶线结果。数据显示，AL001不仅达到了生物等效性的标准，更在所有受测脑区均表现出卓越的脑部递送效果。
Alzamend Neuro公司宣布，其针对AL001（即“锂入脑”研究）的II期临床试验获得了积极的顶线结果。数据显示，AL001不仅达到了生物等效性的标准，更在所有受测脑区均表现出卓越的脑部递送效果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.